Literature DB >> 32875413

Short- and long-term outcomes of laparoscopic versus open lateral lymph node dissection for locally advanced middle/lower rectal cancer using a propensity score-matched analysis.

Jun Watanabe1, Atsushi Ishibe2, Yusuke Suwa3, Mayumi Ozawa2, Kazuya Nakagawa2, Hirokazu Suwa4, Mitsuyoshi Ota3, Chikara Kunisaki3, Itaru Endo2.   

Abstract

BACKGROUND: There are few reports on large-scale trials for the long-term outcomes regarding laparoscopic lateral lymph node dissection (LLND). We evaluated the short- and long-term outcomes of laparoscopic versus open LLND for locally advanced middle/lower rectal cancer using a propensity score-matched analysis.
METHODS: From January 2005 to December 2016, consecutive clinical stage II to III middle/lower rectal cancer patients who underwent total mesorectal excision (TME) plus LLND were retrospectively collected at three institutions. Laparoscopic LLND was compared with open LLND for the surgical and oncological outcomes, including the long-term survival, using a propensity score-matched analysis.
RESULTS: A total of 325 patients were collected. There were 142 patients who underwent open TME plus LLND (open group) and 183 patients who underwent laparoscopic TME plus LLND (laparoscopic group). A total of 93 patients each were matched to each group. Compared to the open group, the laparoscopic group had a significantly longer operative time (327 vs. 377 min; p = 0.002) but significantly less blood loss (540 vs. 50 ml; p < 0.001), fewer Clavian-Dindo grade ≥ 2 postoperative complications (49.5% vs. 34.4%; p = 0.037) and shorter postoperative hospital stay (18 vs. 14 days; p = 0.008). Furthermore, the rate of urinary retention was significantly lower in the laparoscopic group than in the open group (16.1% vs. 6.5%; p = 0.037). The estimated 3-year overall survival, relapse-free survival, and cumulative incidence of local recurrence were 91.4%, 73.1%, and 3.4% in the open group and 90.3%, 74.2%, and 4.3% in the laparoscopic group (p = 0.879, 0.893, 0.999), respectively.
CONCLUSIONS: This study showed that laparoscopic LLND had advantages over an open approach, such as less blood loss, fewer postoperative complications, and a shorter postoperative hospital stay, and the oncologic outcomes were similar to the open approach. Laparoscopic LLND could be a viable standard approach to LLND for advanced middle/lower rectal cancer surgery.

Entities:  

Keywords:  Laparoscopic surgery; Lateral lymph node dissection; Lateral pelvic lymph node; Long-term outcome; Rectal cancer

Year:  2020        PMID: 32875413     DOI: 10.1007/s00464-020-07943-4

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  1 in total

1.  Proton pump inhibitors and the risk of colorectal cancer: a systematic review and meta-analysis of observational studies.

Authors:  Tianyi Ma; Meng Wu; Shengnan Jia; Lanlan Yang
Journal:  Int J Colorectal Dis       Date:  2020-08-18       Impact factor: 2.571

  1 in total
  3 in total

1.  Laparoscopic versus open lateral pelvic lymph node dissection in locally advanced rectal cancer: multicentre retrospective cohort study.

Authors:  Han-Ki Lim; Minjung Kim; Ji Won Park; Seung-Bum Ryoo; Kyu Joo Park; Heung-Kwon Oh; Duck-Woo Kim; Sung-Bum Kang; Dong Woon Lee; Sung Chan Park; Jae Hwan Oh; Seung-Yong Jeong
Journal:  BJS Open       Date:  2022-05-02

2.  Short-Term and Long-Term Outcomes in Mid and Low Rectal Cancer With Robotic Surgery.

Authors:  Jingwen Chen; Zhiyuan Zhang; Wenju Chang; Tuo Yi; Qingyang Feng; Dexiang Zhu; Guodong He; Ye Wei
Journal:  Front Oncol       Date:  2021-03-09       Impact factor: 6.244

3.  The feasibility and technical strategy of a fascia space priority approach in laparoscopic lateral lymph node dissection for advanced middle and low rectal cancer: a retrospective multicentre study.

Authors:  Yi Sun; Lei Lian; Hong Zhang; Xuefeng Bai; Zhongshi Xie; Jun Ouyang; Kai Wang; Hang Yuan; Chang Xu; Henggui Luo; Haijun Deng; Jun Li; Hongjie Yang; Zhichun Zhang; Peng Li; Xipeng Zhang
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2021-04-09       Impact factor: 1.195

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.